|
Index of reports
> Cases with Neutropenia (401)
Below is the selection of side effect reports (a.k.a. adverse event reports) related to Cyclophosphamide where reactions include neutropenia. The selected reports were submitted to the FDA during the sample period of about a year. Reports 1 - 30 of 401 Next >>
Possible Cyclophosphamide side effects in
Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-27
Patient:
Reactions: Off Label Use, Gastrointestinal Toxicity, Neutropenia, Infection
Drug(s) suspected as cause:
Carboplatin
Dosage: 6 courses in high risk
Indication: Retinoblastoma
Cyclophosphamide
Indication: Retinoblastoma
Doxorubicin Hydrochloride
Dosage: 4 courses in intermediate risk and 6 courses in high risk
Indication: Retinoblastoma
Etoposide
Indication: Retinoblastoma
Vincristine
Dosage: 4 courses in intermediate risk and 6 courses in high risk
Indication: Retinoblastoma
Other drugs received by patient: Neupogen
Possible Cyclophosphamide side effects in male
Reported by a physician from Germany on 2012-08-24
Patient: male
Reactions: Febrile Neutropenia, Skin Infection, Neutropenia, Pneumonitis
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 1500 mg, unk
Indication: B-Cell Lymphoma
Start date: 2012-02-02
End date: 2012-04-17
Doxorubicin Hydrochloride
Dosage: 100 mg, unk
Indication: B-Cell Lymphoma
Start date: 2012-02-02
End date: 2012-04-17
Neulasta
Dosage: 6 mg, unk
Indication: B-Cell Lymphoma
Start date: 2012-02-06
End date: 2012-04-20
Prednisolone
Dosage: 100 mg, unk
Administration route: Oral
Indication: B-Cell Lymphoma
Start date: 2012-02-02
End date: 2012-04-21
Rituximab
Dosage: 750 mg, unk
Indication: B-Cell Lymphoma
Start date: 2012-02-01
End date: 2012-04-16
Vincristine
Dosage: 2 mg, unk
Indication: B-Cell Lymphoma
Start date: 2012-02-02
End date: 2012-04-17
Other drugs received by patient: MST / 00036302 /; Novalgin / 00169801 /; Rulid; Pantoprazole; Paspertin / 00041902 /; Acyclovir; Electrolytes NOS W / Macrogol 3350; Dipyrone INJ; Metoclopramide; Acyclovir
Possible Cyclophosphamide side effects in male
Reported by a physician from United States on 2012-08-24
Patient: male, weighing 26.9 kg (59.2 pounds)
Reactions: Tachycardia, Fungal Sepsis, Status Epilepticus, Oral Candidiasis, Hypomagnesaemia, Acute Respiratory Distress Syndrome, Bradycardia, Neutropenia, Blood Pressure Decreased, Shock
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
C-CSF (Filgrastim, Amgen)
Dosage: 135 mg
Cisplatin
Dosage: 74 mg
Cyclophosphamide
Dosage: 1960 mg
Isotretinoin
Dosage: 80 mg
Vincristine Sulfate
Dosage: 2.8 mg
Possible Cyclophosphamide side effects in female
Reported by a physician from Thailand on 2012-08-24
Patient: female, weighing 57.4 kg (126.3 pounds)
Reactions: Neutropenia
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Indication: B-Cell Lymphoma
Start date: 2012-03-02
Doxorubicin Hydrochloride
Indication: B-Cell Lymphoma
Start date: 2012-03-02
Mabthera
Indication: B-Cell Lymphoma
Start date: 2012-03-02
Prednisone TAB
Indication: B-Cell Lymphoma
Start date: 2012-03-02
Vincristine
Indication: B-Cell Lymphoma
Start date: 2012-03-02
Other drugs received by patient: Dexamethasone; Acetaminophen; Ondansetron; Metformin HCL; Ondansetron; Ondansetron; Atenolol; Simvastatin; Benadryl
Possible Cyclophosphamide side effects in 65 year old female
Reported by a physician from Japan on 2012-08-24
Patient: 65 year old female, weighing 50.2 kg (110.6 pounds)
Reactions: Weight Decreased, Blood Bilirubin Increased, Cytomegalovirus Viraemia, Headache, Pyrexia, Interstitial Lung Disease, Oedema, Thrombocytopenia, Blood Sodium Decreased, Decreased Appetite, Vomiting, Stomatitis, Pneumonia, Alanine Aminotransferase Increased, Lymphopenia, Anaemia, Febrile Neutropenia, Rash, Blood Phosphorus Decreased, Blood Potassium Decreased, Diarrhoea, Alopecia, Aspartate Aminotransferase Increased, Neutropenia, Leukopenia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Adriamycin PFS
Dosage: 30 mg/m2 x 1/4 week
Start date: 2011-03-16
Adriamycin PFS
Dosage: 40 mg/m2 x 1/4 week
Indication: Adult T-Cell Lymphoma / Leukaemia
Start date: 2011-03-09
Carboplatin
Dosage: 250 mg/m2 x 1/4 week
Indication: Adult T-Cell Lymphoma / Leukaemia
Start date: 2011-03-24
Cyclophosphamide
Dosage: 350 mg/m2 x 1/4 week
Indication: Adult T-Cell Lymphoma / Leukaemia
Start date: 2011-03-09
Etoposide
Dosage: 100 mg/m2 x 1/4 week
Indication: Adult T-Cell Lymphoma / Leukaemia
Start date: 2011-03-24
Prednisolone
Dosage: 40 mg/m2 x 1/4 week
Administration route: Oral
Indication: Adult T-Cell Lymphoma / Leukaemia
Start date: 2011-03-09
Prednisolone
Dosage: 1mg/kg x 1/2 week
Start date: 2011-12-13
End date: 2011-12-14
Prednisolone
Dosage: 40 mg/m2 x 1/4 week
Administration route: Oral
Start date: 2011-03-16
Prednisolone
Dosage: 2 mg/m2, 1x/day
Administration route: Oral
Start date: 2011-03-24
Ranimustine
Dosage: 60 mg/m2 x 1/4 week
Indication: Adult T-Cell Lymphoma / Leukaemia
Start date: 2011-03-16
Vincristine Sulfate
Dosage: 1 mg/m2 x 1/4 week
Indication: Adult T-Cell Lymphoma / Leukaemia
Start date: 2011-03-09
Vindesine Sulfate
Dosage: 2.4 mg/m2 x 1/4 week
Indication: Adult T-Cell Lymphoma / Leukaemia
Start date: 2011-03-24
Other drugs received by patient: Mucosolvan; Lansoprazole; Sulfamethoxazole and Trimethoprim; Armodafinil; Zolpidem; Olopatadine HCL; Cefazolin Sodium; Ciprofloxacin HCL; Armodafinil; Zovirax; Magmitt; Alendronate Sodium
Possible Cyclophosphamide side effects in 52 year old female
Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-24
Patient: 52 year old female
Reactions: Tumour Lysis Syndrome, Posterior Reversible Encephalopathy Syndrome, Insomnia, Neutropenia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: according to larson regimen
Indication: B Precursor Type Acute Leukaemia
Daunorubicin HCL
Dosage: according to larson regimen
Indication: B Precursor Type Acute Leukaemia
Daunorubicin HCL
Dosage: at 50% dosage
Dexamethasone
Indication: Premedication
Methylprednisolone Sodium Succinate
Indication: B Precursor Type Acute Leukaemia
Prednisone TAB
Dosage: according to larson regimen
Indication: B Precursor Type Acute Leukaemia
Vincristine
Dosage: according to larson regimen
Indication: B Precursor Type Acute Leukaemia
Other drugs received by patient: Ondansetron; Voriconazole; Morphine Sulfate; Morphine
Possible Cyclophosphamide side effects in male
Reported by a individual with unspecified qualification from United States on 2012-08-23
Patient: male, weighing 26.9 kg (59.2 pounds)
Reactions: Abdominal Pain, Dyspnoea, Dilatation Ventricular, Tachycardia, Fungal Sepsis, Status Epilepticus, Pyrexia, Hemiparesis, Breath Sounds Abnormal, Hypophagia, Hypomagnesaemia, Acute Respiratory Distress Syndrome, Shunt Malfunction, Neutropenia, Blood Pressure Decreased, Shock
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cisplatin
Dosage: 74 mg
Cyclophosphamide
Dosage: 1960 mg
G-CSF (Filgrastim, Amgen)
Dosage: 135 mg
Isotretinoin
Dosage: 80 mg
Vincristine Sulfate
Dosage: 2.8 mg
Possible Cyclophosphamide side effects in female
Reported by a individual with unspecified qualification from United States on 2012-08-23
Patient: female, weighing 81.8 kg (180.0 pounds)
Reactions: Dyspnoea, Chest Pain, Pancytopenia, Pyrexia, Neutropenia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 1400 mg
Doxorubicin Hydrochloride
Dosage: 94 mg
Prednisone
Dosage: 375 mg
Rituximab (Moab C2b8 Anti Cd20, Chimeric)
Dosage: 700 mg
Vincristine Sulfate
Dosage: 2 mg
Possible Cyclophosphamide side effects in male
Reported by a physician from United States on 2012-08-22
Patient: male, weighing 94.0 kg (206.8 pounds)
Reactions: Tachycardia, Clostridium Difficile Colitis, Pancytopenia, Neutropenia, Pyrexia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 2780 mg
Doxorubicin Hydrochloride
Dosage: 152 mg
Etoposide
Dosage: 720 mg
Fluorine-18 2-Fluorou-2 Deoxyry-D-Glucose (18f-Fdg)
Dosage: 12 mg
Prednisone
Dosage: 1300 mg
Rituximab
Dosage: 800 mg
Vincristine Sulfate
Dosage: 3.6 mg
Possible Cyclophosphamide side effects in
Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-21
Patient:
Reactions: Off Label Use, Gastrointestinal Toxicity, Neutropenia, Infection
Drug(s) suspected as cause:
Carboplatin
Dosage: 6 courses in high risk
Indication: Retinoblastoma
Cyclophosphamide
Indication: Retinoblastoma
Doxorubicin HCL
Dosage: 4 courses in intermediate risk and 6 courses in high risk
Indication: Retinoblastoma
Etoposide
Indication: Retinoblastoma
Vincristine
Dosage: 4 courses in intermediate risk and 6 courses in high risk
Indication: Retinoblastoma
Other drugs received by patient: Neupogen
Possible Cyclophosphamide side effects in
Reported by a individual with unspecified qualification from United States on 2012-08-21
Patient: , weighing 61.4 kg (135.1 pounds)
Reactions: Neutropenia, Enterocolitis
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Carboplatin
Dosage: 2150 mg
Start date: 2012-07-13
Cyclophosphamide
Dosage: 1000 mg
Start date: 2012-08-09
Doxorubicin Hydrochloride
Dosage: 100 mg
Start date: 2012-08-09
Taxol
Dosage: 1242 mg
Start date: 2012-08-03
Possible Cyclophosphamide side effects in male
Reported by a health professional (non-physician/pharmacist) from France on 2012-08-20
Patient: male
Reactions: Neutropenia, Infection
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Start date: 2012-05-21
End date: 2012-05-21
Cyclophosphamide
Start date: 2012-07-02
End date: 2012-07-02
Cyclophosphamide
Start date: 2012-07-23
End date: 2012-07-23
Cyclophosphamide
Start date: 2012-06-11
End date: 2012-06-11
Doxorubicin Hydrochloride
Start date: 2012-05-21
End date: 2012-05-21
Doxorubicin Hydrochloride
Start date: 2012-06-11
End date: 2012-06-11
Doxorubicin Hydrochloride
Start date: 2012-07-23
End date: 2012-07-23
Doxorubicin Hydrochloride
Start date: 2012-07-02
End date: 2012-07-02
Etopophos Preservative Free
Start date: 2012-06-11
End date: 2012-06-11
Etopophos Preservative Free
Start date: 2012-07-02
End date: 2012-07-02
Etopophos Preservative Free
Start date: 2012-07-23
End date: 2012-07-23
Etopophos Preservative Free
Start date: 2012-05-21
End date: 2012-05-21
Mabthera
Start date: 2012-05-21
End date: 2012-05-21
Mabthera
Start date: 2012-07-02
End date: 2012-07-02
Mabthera
Start date: 2012-06-11
End date: 2012-06-11
Mabthera
Start date: 2012-07-23
End date: 2012-07-23
Other drugs received by patient: Acetaminophen; Lovenox; Nexium; Crestor; Clopidogrel Bisulfate and Aspirin; Valacyclovir Hydrochloride; Acebutolol
Possible Cyclophosphamide side effects in
Reported by a health professional (non-physician/pharmacist) from Italy on 2012-08-20
Patient:
Reactions: Abdominal Pain, Vomiting, Hypersensitivity, Nausea, Skin Toxicity, Mucosal Inflammation, Fatigue, Diarrhoea, Hepatotoxicity, Neutropenia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Indication: Breast Cancer
Epirubicin
Indication: Breast Cancer
Fluorouracil
Indication: Breast Cancer
Herceptin
Dosage: loading dose
Indication: Breast Cancer
Herceptin
Dosage: maintenance dose
Lapatinib
Dosage: arm b
Administration route: Oral
Indication: Breast Cancer
Lapatinib
Dosage: arm c
Administration route: Oral
Paclitaxel
Indication: Breast Cancer
Possible Cyclophosphamide side effects in 55 year old female
Reported by a health professional (non-physician/pharmacist) from Japan on 2012-08-18
Patient: 55 year old female
Reactions: Malaise, Neutropenia, Wound Infection
Drug(s) suspected as cause:
Cyclophosphamide
Indication: Breast Cancer
Dexamethasone
Dosage: 8 mg
Dexamethasone
Dosage: 8 mg
Administration route: Oral
Indication: Supportive Care
Docetaxel
Indication: Breast Cancer
Possible Cyclophosphamide side effects in female
Reported by a physician from United States on 2012-08-16
Patient: female
Reactions: Abdominal Pain, Vomiting, Nausea, Palmar-Plantar Erythrodysaesthesia Syndrome, Febrile Neutropenia, Peripheral Sensory Neuropathy, Constipation, Fatigue, Diarrhoea, Neutropenia
Drug(s) suspected as cause:
Adriamycin PFS
Dosage: cycle 3
Adriamycin PFS
Dosage: cycle 4
Adriamycin PFS
Dosage: cycle 2
Adriamycin PFS
Dosage: cycle 1
Indication: Breast Cancer
Cyclophosphamide
Dosage: cycle 4
Cyclophosphamide
Dosage: cycle 3
Indication: Breast Cancer
Cyclophosphamide
Dosage: cycle 1
Cyclophosphamide
Dosage: cycle 2
Docetaxel
Dosage: cycle 4
Docetaxel
Dosage: cycle 3
Indication: Breast Cancer
Docetaxel
Dosage: cycle 2
Docetaxel
Dosage: cycle 1
Doxorubicin Hydrochloride
Dosage: cycle 3
Doxorubicin Hydrochloride
Dosage: cycle 4
Indication: Breast Cancer
Doxorubicin Hydrochloride
Dosage: cycle 1
Doxorubicin Hydrochloride
Dosage: cycle 2
NOV-002
NOV-002
Dosage: administered approximately 3 hr apart
Indication: Breast Cancer
NOV-002
Possible Cyclophosphamide side effects in
Reported by a physician from United States on 2012-08-16
Patient:
Reactions: Nausea, Pain, Motor Dysfunction, Rash, Peripheral Sensory Neuropathy, Fatigue, Blood Potassium Decreased, Dyspepsia, Diarrhoea, Neutropenia, Thrombocytopenia
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: on day 1
Cyclophosphamide
Dosage: on day 1
Indication: Lymphocytic Lymphoma
Cyclophosphamide
Dosage: on day 1
Indication: non-Hodgkin's Lymphoma
Cyclophosphamide
Dosage: on day 1
Indication: B-Cell Lymphoma
Cyclophosphamide
Dosage: on day 1
Indication: Lymphoma
Cyclophosphamide
Dosage: on day 1
Indication: Waldenstrom's Macroglobulinaemia
Doxorubicin HCL
Dosage: on day 1
Indication: non-Hodgkin's Lymphoma
Doxorubicin HCL
Dosage: on day 1
Doxorubicin HCL
Dosage: on day 1
Doxorubicin HCL
Dosage: on day 1
Indication: Lymphoma
Doxorubicin HCL
Dosage: on day 1
Doxorubicin HCL
Dosage: on day 1
Indication: Waldenstrom's Macroglobulinaemia
Doxorubicin HCL
Dosage: on day 1
Indication: B-Cell Lymphoma
Doxorubicin HCL
Dosage: on day 1
Doxorubicin HCL
Dosage: on day 1
Indication: Lymphocytic Lymphoma
Doxorubicin HCL
Dosage: on day 1
Doxorubicin HCL
Dosage: on day 1
Doxorubicin HCL
Dosage: on day 1
Prednisone TAB
Dosage: on days 1-5
Administration route: Oral
Indication: B-Cell Lymphoma
Prednisone TAB
Dosage: on days 1-5
Administration route: Oral
Indication: Waldenstrom's Macroglobulinaemia
Prednisone TAB
Dosage: on days 1-5
Administration route: Oral
Indication: non-Hodgkin's Lymphoma
Prednisone TAB
Dosage: on days 1-5
Administration route: Oral
Prednisone TAB
Dosage: on days 1-5
Administration route: Oral
Indication: Lymphoma
Prednisone TAB
Dosage: on days 1-5
Administration route: Oral
Indication: Lymphocytic Lymphoma
Rituximab
Dosage: on day 1
Indication: Waldenstrom's Macroglobulinaemia
Rituximab
Dosage: on day 1
Rituximab
Dosage: maintenance
Rituximab
Dosage: on day 1
Rituximab
Dosage: maintenance
Indication: Lymphocytic Lymphoma
Rituximab
Dosage: maintenance
Indication: B-Cell Lymphoma
Rituximab
Dosage: on day 1
Rituximab
Dosage: maintenance
Indication: non-Hodgkin's Lymphoma
Rituximab
Dosage: on day 1
Rituximab
Dosage: maintenance
Rituximab
Dosage: maintenance
Indication: Lymphoma
Rituximab
Dosage: on day 1
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Indication: B-Cell Lymphoma
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Indication: Lymphoma
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Indication: Waldenstrom's Macroglobulinaemia
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Indication: Lymphocytic Lymphoma
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Indication: non-Hodgkin's Lymphoma
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: non-Hodgkin's Lymphoma
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: Waldenstrom's Macroglobulinaemia
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: Lymphoma
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: B-Cell Lymphoma
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: Lymphocytic Lymphoma
Other drugs received by patient: Acetaminophen; Diphenhydramine Hydrochloride; Ondansetron
Possible Cyclophosphamide side effects in female
Reported by a health professional (non-physician/pharmacist) from Norway on 2012-08-16
Patient: female
Reactions: Colitis, Neutropenia
Drug(s) suspected as cause:
Azathioprine Sodium
Indication: Wegener's Granulomatosis
Cellcept
Indication: Wegener's Granulomatosis
Cyclophosphamide
Indication: Wegener's Granulomatosis
Everolimus
Indication: Wegener's Granulomatosis
Immune Globulin NOS
Indication: Wegener's Granulomatosis
Mabthera
Dosage: given after 1 month from the event
Indication: Wegener's Granulomatosis
Start date: 2006-11-01
Mabthera
Indication: Rheumatoid Arthritis
Start date: 2006-11-01
Methotrexate
Indication: Wegener's Granulomatosis
Methotrexate
Indication: Off Label Use
Tacrolimus
Indication: Wegener's Granulomatosis
Other drugs received by patient: Prednisolone
Possible Cyclophosphamide side effects in male
Reported by a health professional (non-physician/pharmacist) from Norway on 2012-08-15
Patient: male
Reactions: Neutropenia
Drug(s) suspected as cause:
Azathioprine Sodium
Indication: Wegener's Granulomatosis
Cyclophosphamide
Indication: Wegener's Granulomatosis
Cyclophosphamide
Indication: Pancytopenia
Immune Globulin Intravenous (Human)
Indication: Wegener's Granulomatosis
Immune Globulin Intravenous (Human)
Indication: Hypogammaglobulinaemia
Mabthera
Indication: Rheumatoid Arthritis
Start date: 2007-03-01
Mabthera
Dosage: given after 2 months from the event
Indication: Wegener's Granulomatosis
Methotrexate
Indication: Truss User
Methotrexate
Indication: Wegener's Granulomatosis
Other drugs received by patient: Prednisolone
Possible Cyclophosphamide side effects in 64 year old male
Reported by a health professional (non-physician/pharmacist) from Italy on 2012-08-08
Patient: 64 year old male
Reactions: Pneumonia, Neutropenia, Leukaemia Plasmacytic, Disease Progression
Adverse event resulted in: death
Drug(s) suspected as cause:
Bortezomib
Indication: Leukaemia Plasmacytic
Cyclophosphamide
Dosage: 1 g
Indication: Leukaemia Plasmacytic
Dexamethasone
Dosage: 40 mg
Dexamethasone
Dosage: 40 mg
Indication: Leukaemia Plasmacytic
Lenalidomide
Dosage: 25 mg
Indication: Leukaemia Plasmacytic
Possible Cyclophosphamide side effects in
Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-07
Patient:
Reactions: Hospitalisation, Neuropathy Peripheral, Vomiting, Febrile Neutropenia, Neutropenia, Neutrophil Count Decreased, Lymphoma
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Indication: B-Cell Lymphoma
Cyclophosphamide
Indication: Diffuse Large B-Cell Lymphoma
Doxorubicin Hydrochloride
Indication: B-Cell Lymphoma
Doxorubicin Hydrochloride
Indication: Diffuse Large B-Cell Lymphoma
Prednisone
Dosage: for 5 days
Indication: B-Cell Lymphoma
Prednisone
Dosage: for 5 days
Indication: Diffuse Large B-Cell Lymphoma
Radiotherapy
Indication: Diffuse Large B-Cell Lymphoma
Radiotherapy
Indication: B-Cell Lymphoma
Rituximab
Indication: B-Cell Lymphoma
Rituximab
Indication: Diffuse Large B-Cell Lymphoma
Vincristine
Indication: B-Cell Lymphoma
Vincristine
Indication: Diffuse Large B-Cell Lymphoma
Other drugs received by patient: Neupogen
Possible Cyclophosphamide side effects in
Reported by a physician from Spain on 2012-08-06
Patient:
Reactions: Skin Toxicity, Sudden Death, Hepatic Failure, Encephalitis, Cytomegalovirus Colitis, Pneumonia Pneumococcal, Neurotoxicity, Death, Multi-Organ Failure, Metastasis, Cardiotoxicity, AIDS Dementia Complex, Pseudomonas Infection, Toxicity To Various Agents, Staphylococcal Infection, Pneumonia Herpes Viral, Neutropenia, Escherichia Infection, Infection
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: given on day 1 of the 3 week cycle
Indication: Lymphoma AIDS Related
Doxorubicin HCL
Dosage: given on day 1 of the 3 week cycle
Indication: Lymphoma AIDS Related
Mabthera
Dosage: given on day 1 of every 3 week cycle (prior to chop)
Indication: Lymphoma AIDS Related
Prednisone TAB
Dosage: given for 5 days
Administration route: Oral
Indication: Lymphoma AIDS Related
Vincristine Sulfate
Dosage: given on day 1 of 3 week cycle.
Indication: Lymphoma AIDS Related
Other drugs received by patient: Hydrocortisone; Cytarabine; Methotrexate
Possible Cyclophosphamide side effects in 76 year old
Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-02
Patient: 76 year old
Reactions: Lung Disorder, Neutropenia, Infection
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Indication: Diffuse Large B-Cell Lymphoma
Doxorubicin Hydrochloride
Indication: Diffuse Large B-Cell Lymphoma
Prednisone
Dosage: daily for 5 days
Indication: Diffuse Large B-Cell Lymphoma
Radiotherapy
Indication: Diffuse Large B-Cell Lymphoma
Rituximab
Indication: Diffuse Large B-Cell Lymphoma
Vincristine
Indication: Diffuse Large B-Cell Lymphoma
Other drugs received by patient: Neupogen
Possible Cyclophosphamide side effects in 58 year old male
Reported by a health professional (non-physician/pharmacist) on 2012-08-02
Patient: 58 year old male, weighing 77.0 kg (169.4 pounds)
Reactions: Haemoglobin Decreased, White Blood Cell Count Decreased, Platelet Count Decreased, Neutropenia
Drug(s) suspected as cause:
Asparaginase (Unspecified) (Asparginase) (Unknown)
Indication: Chemotherapy
Start date: 2012-03-12
Cyclophosphamide
Indication: Chemotherapy
Start date: 2012-03-12
Dexamethasone
Indication: Chemotherapy
Start date: 2012-03-12
Doxorubicin HCL
Indication: Chemotherapy
Start date: 2012-03-12
Isavuconazole (Isavuconazole)
Dosage: three times daily, intravenous (not otherwise specified)
Indication: Fungal Infection
Start date: 2012-02-07
End date: 2012-02-09
Vincristine
Indication: Chemotherapy
Start date: 2012-03-12
Other drugs received by patient: Metronidazole; Ciprofloxacin
Possible Cyclophosphamide side effects in
Reported by a physician from United States on 2012-08-01
Patient:
Reactions: Nausea, Motor Dysfunction, Pain, Rash, Peripheral Sensory Neuropathy, Fatigue, Dyspepsia, Blood Potassium Decreased, Diarrhoea, Neutropenia, Thrombocytopenia
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: on day 1
Indication: Waldenstrom's Macroglobulinaemia
Cyclophosphamide
Dosage: on day 1
Indication: B-Cell Lymphoma
Cyclophosphamide
Dosage: on day 1
Indication: Lymphoma
Cyclophosphamide
Dosage: on day 1
Indication: non-Hodgkin's Lymphoma
Cyclophosphamide
Dosage: on day 1
Indication: Lymphocytic Lymphoma
Cyclophosphamide
Dosage: on day 1
Doxorubicin Hydrochloride
Dosage: on day 1
Indication: Waldenstrom's Macroglobulinaemia
Doxorubicin Hydrochloride
Dosage: on day 1
Indication: Lymphoma
Doxorubicin Hydrochloride
Dosage: on day 1
Indication: non-Hodgkin's Lymphoma
Doxorubicin Hydrochloride
Dosage: on day 1
Indication: Lymphocytic Lymphoma
Doxorubicin Hydrochloride
Dosage: on day 1
Doxorubicin Hydrochloride
Dosage: on day 1
Indication: B-Cell Lymphoma
Prednisone
Dosage: on days 1-5
Administration route: Oral
Indication: Lymphoma
Prednisone
Dosage: on days 1-5
Administration route: Oral
Indication: B-Cell Lymphoma
Prednisone
Dosage: on days 1-5
Administration route: Oral
Indication: Waldenstrom's Macroglobulinaemia
Prednisone
Dosage: on days 1-5
Administration route: Oral
Indication: Lymphocytic Lymphoma
Prednisone
Dosage: on days 1-5
Administration route: Oral
Prednisone
Dosage: on days 1-5
Administration route: Oral
Indication: non-Hodgkin's Lymphoma
Rituximab
Dosage: maintenance
Indication: Waldenstrom's Macroglobulinaemia
Rituximab
Dosage: maintenance
Rituximab
Dosage: on day 1
Indication: Lymphocytic Lymphoma
Rituximab
Dosage: maintenance
Rituximab
Dosage: on day 1
Rituximab
Dosage: on day 1
Indication: B-Cell Lymphoma
Rituximab
Dosage: on day 1
Indication: non-Hodgkin's Lymphoma
Rituximab
Dosage: maintenance
Rituximab
Dosage: maintenance
Rituximab
Dosage: on day 1
Indication: Lymphoma
Rituximab
Dosage: maintenance
Rituximab
Dosage: on day 1
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Indication: non-Hodgkin's Lymphoma
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Indication: B-Cell Lymphoma
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Indication: Lymphoma
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Indication: Lymphocytic Lymphoma
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Indication: Waldenstrom's Macroglobulinaemia
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: Waldenstrom's Macroglobulinaemia
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: Lymphocytic Lymphoma
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: B-Cell Lymphoma
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: non-Hodgkin's Lymphoma
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: Lymphoma
Other drugs received by patient: Diphenhydramine HCL; Acetaminophen; Ondansetron
Possible Cyclophosphamide side effects in
Reported by a physician from United Kingdom on 2012-08-01
Patient:
Reactions: Neutropenia, Infection
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 1440 mg, unk
Indication: Mantle Cell Lymphoma
Doxorubicin Hydrochloride
Dosage: 96 mg, unk
Indication: Mantle Cell Lymphoma
Prednisone
Dosage: 100 mg, unk
Indication: Mantle Cell Lymphoma
Prednisone
Dosage: 80 unk, unk
Velcade
Dosage: 3 mg, unk
Indication: Mantle Cell Lymphoma
Start date: 2011-01-27
Vincristine
Indication: Mantle Cell Lymphoma
Other drugs received by patient: Sando K / 00031402 /
Possible Cyclophosphamide side effects in male
Reported by a health professional (non-physician/pharmacist) from United Kingdom on 2012-08-01
Patient: male
Reactions: Neutropenia
Drug(s) suspected as cause:
Cyclophosphamide
Indication: B-Cell Lymphoma
Doxorubicin Hydrochloride
Indication: B-Cell Lymphoma
Mabthera
Indication: B-Cell Lymphoma
Prednisone
Indication: B-Cell Lymphoma
Vincristine
Indication: B-Cell Lymphoma
Possible Cyclophosphamide side effects in
Reported by a health professional (non-physician/pharmacist) from Russian Federation on 2012-07-31
Patient:
Reactions: Vomiting, Acute Leukaemia, Febrile Neutropenia, Treatment Failure, Neutropenia, Toxicity To Various Agents, Neoplasm, Leukopenia
Adverse event resulted in: death
Drug(s) suspected as cause:
Bleomycin Sulfate
Dosage: as part of abvd or beacopp
Indication: Hodgkin's Disease
Chemoradiation
Indication: Hodgkin's Disease
Cyclophosphamide
Indication: Hodgkin's Disease
Dacarbazine
Indication: Hodgkin's Disease
Doxorubicin Hydrochloride
Dosage: as part of abvd or beacopp
Indication: Hodgkin's Disease
Etoposide
Indication: Hodgkin's Disease
Prednisone
Indication: Hodgkin's Disease
Procarbazine Hydrochloride
Indication: Hodgkin's Disease
Vinblastine Sulfate
Indication: Hodgkin's Disease
Vincristine
Indication: Hodgkin's Disease
Possible Cyclophosphamide side effects in 70 year old female
Reported by a health professional (non-physician/pharmacist) from United Kingdom on 2012-07-30
Patient: 70 year old female
Reactions: Renal Impairment, Hyperkalaemia, Anaemia, Neutropenia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Administration route: Oral
Indication: Multiple Myeloma
Start date: 2010-09-24
End date: 2010-11-03
Dexamethasone
Indication: Multiple Myeloma
Start date: 2010-09-24
End date: 2010-11-03
Revlimid
Dosage: 10 milligram
Administration route: Oral
Indication: Multiple Myeloma
Start date: 2010-09-24
End date: 2010-11-03
Possible Cyclophosphamide side effects in male
Reported by a health professional (non-physician/pharmacist) from United Kingdom on 2012-07-27
Patient: male
Reactions: Neutropenia, Haematotoxicity
Drug(s) suspected as cause:
(Mabthera)
Indication: B-Cell Lymphoma
Cyclophosphamide
Indication: B-Cell Lymphoma
Doxorubicin Hydrochloride
Indication: B-Cell Lymphoma
Prednisone TAB
Indication: B-Cell Lymphoma
Vincristine Sulfate
Indication: B-Cell Lymphoma
Possible Cyclophosphamide side effects in female
Reported by a health professional (non-physician/pharmacist) from Germany on 2012-07-27
Patient: female, weighing 67.7 kg (148.9 pounds)
Reactions: Febrile Neutropenia, Neutropenia, Bronchitis, Thrombocytopenia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Start date: 2012-05-24
Cyclophosphamide
Start date: 2012-04-12
Epirubicin Hydrochloride
Start date: 2012-05-24
Epirubicin Hydrochloride
Start date: 2012-04-12
Fluorouracil
Start date: 2012-04-12
Fluorouracil
Start date: 2012-05-24
Other drugs received by patient: Nobiten; Pantoprazole; Simvastatine EG; Escitalopram Oxalate
Page 1 Next >>
|
